Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) has been adopted worldwide as an imaging modality for prostate cancer (PCa) and has shown a promising role for the initial staging [1, 2]. This evidence concerns the gene FOLH1 and prostate carcinoma.